Neuroepithelial cell-transforming gene 1 protein (NET1)

Neuroepithelial cell-transforming gene 1 protein (NET1) is a RhoA-specific guanine nucleotide exchange factor (GEF) that catalyzes the activation of the small GTPase RhoA by promoting GDP–GTP exchange[1][3][4]. NET1 orchestrates cytoskeletal dynamics, cell adhesion, and motility by stimulating actin stress fiber and focal adhesion formation, which modulates extracellular matrix degradation and promotes invasive cellular behavior[1][3]. Its activity is controlled by subcellular localization, phosphorylation, and protein–protein interactions, with nuclear–cytoplasmic shuttling playing a key role in its regulation[1]. Aberrant or elevated NET1 expression is strongly linked to tumor progression, invasion, metastasis, and chemoresistance in several human cancers, and it may serve as both a prognostic biomarker and an emerging therapeutic target[1][3][2]. While targeting the NET1–RhoA interaction has shown experimental promise as an anticancer strategy[2], no clinically approved drugs against NET1 currently exist.

Other names

NET1ARHGEF8NET1AProto-oncogene p65 Net1Rho guanine nucleotide exchange factor 8Neuroepithelial cell transforming 1Small GTP-binding protein regulatorNeuroepithelioma transforming gene 1p65 Net1 proto-oncogene protein

Inhibitors or peptides that disrupt NET1–RhoA binding block guanine nucleotide exchange on RhoA, inhibiting downstream RhoA-mediated signaling involved in cancer cell invasion and motility[2].